|
|
||||||||
1 Cardiovascular Division, Veterans Affairs Medical Center, and University of Utah Health Sciences Center, Salt Lake City, Utah 84132; and 2 Cardiovascular Section, University Heart Center and Veterans Affairs Medical Center, Tucson, Arizona 85723
| |
ABSTRACT |
|---|
|
|
|---|
Loss of the positive
force-frequency relationship is a characteristic finding in failing
hearts. The mechanisms of this change are not well understood.
Myocardial infarction (MI) was induced in rabbits to produce left
ventricular (LV) dysfunction. Beginning 1 day after MI, a subgroup of
rabbits received diiodothyropropionic acid (DITPA) (3.75 mg · kg
1 · day
1
sc) for 3 wk. We measured contractions, Ca2+ transients,
action potentials, and sarcoplasmic reticulum (SR) Ca2+
content at different stimulation rates in single LV myocytes. The
shortening-frequency relationship was markedly flattened in MI myocytes
compared with control myocytes. In addition, Ca2+
transients, action potentials, and contractions were prolonged. Myocytes from DITPA-treated MI rabbits had preserved inotropic responses to increased stimulation rate and normal duration of action
potentials and Ca2+ transients. SR Ca2+ content
increased significantly when stimulation rate was increased from 0.5 to
2.0 Hz in control myocytes but did not change significantly in MI
myocytes. Myocytes from DITPA-treated MI rabbits had a greater frequency-dependent increase in SR Ca2+ content compared
with the untreated MI rabbits. Thus single myocytes from infarcted
rabbit hearts have frequency-dependent abnormalities of contractility,
Ca2+ cycling, and action potential repolarization. The
flattened contraction-frequency relationship can be partially explained
by an attenuation of the normal enhancement of SR Ca2+
content that occurs when stimulation rate is increased. Chronic DITPA
administration after MI largely prevents the development of these abnormalities.
myocardial infarction; calcium; ion channels; congestive heart failure; sarcoplasmic reticulum; rabbit; contractility; thyroid hormone; diiodothyropropionic acid
| |
INTRODUCTION |
|---|
|
|
|---|
IN NORMAL HEARTS, contractility is enhanced as stimulation rate increases. Loss of the positive force-frequency relationship has been reported in both human tissue and animal models of heart failure (3, 11, 20, 22). The normal enhancement of contractility that occurs with increases in stimulation rate is due to both increased Ca2+ uptake and augmented Ca2+ release from the sarcoplasmic reticulum (SR) (6). By inference, impaired SR function in heart failure may contribute to the loss of frequency potentiation (16). Therefore, enhancing SR function might be expected to improve force-frequency relationships in heart failure. Unfortunately, treatments that act via cAMP-dependent pathways (i.e., phosphodiesterase inhibitors) increase mortality in patients with heart failure (30). Nonetheless, treatments that could improve SR function without increasing cAMP concentrations are theoretically attractive.
Thyroid hormone (T4) therapies have been proposed for the treatment of heart failure because T4 induces expression of sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) and the ryanodine receptor, and decreases expression of phospholamban (2). Because of the potential adverse effects of chronic treatment with T4 (tachycardia and metabolic stimulation), there has been interest in developing T4 analogs that could improve cardiac performance without the other undesired effects. Diiodothyropropionic acid (DITPA) is a T4 analog that produces increases in peak first derivative of pressure with respect to time over a wide dosing range, but with only half of the chronotropic effect and the general metabolic stimulation of T4 (26). DITPA treatment lowers left ventricular (LV) end-diastolic pressure and improves resting and stressed cardiac output in rats and rabbits with postinfarction LV dysfunction (21, 27).
Thyroid hormone treatment enhances the in vivo force-frequency and relaxation-frequency relationships in normal primates (19). DITPA treatment produces similar effects in normal primates, except that chronic DITPA treatment is not associated with shifts in myosin isoforms or with an increase in resting heart rate (17). The effects of T4 or DITPA on force-frequency relationships in the failing heart have not previously been investigated. The goal of these studies was to test the hypothesis that DITPA treatment would prevent the abnormal force-frequency relationship in the diseased heart. In these studies, we employed a model of LV dysfunction due to myocardial infarction (MI) in the rabbit. This model has the advantages of strong clinical relevance (12) and a higher degree of similarity to human myocyte physiology than is seen in smaller rodents. In particular, the action potential morphology, myosin isoform profile, relative dependence on the SR as a source of activator Ca2+, and force-frequency relationships in rabbit myocytes more closely resemble those in human myocytes than do those in the rat or the mouse (14).
| |
METHODS |
|---|
|
|
|---|
Male New Zealand White rabbits weighing 2.5-3.5 kg were used for all experiments. Animals were cared for according to the guidelines of the American Physiological Society. The studies were approved by the institutional animal care committees.
Production of myocardial infarction.
MI was produced by ligating the circumflex artery as described
previously (20, 21). In a minority of rabbits the circumflex artery is
very small or intramyocardial in location and cannot be ligated. Two
such rabbits were included along with twelve unoperated rabbits in the
control group. Rabbits with MI were randomly assigned to DITPA (Sigma)
or no treatment beginning on the first postoperative day. DITPA was
administered at a dose of 3.75 mg · kg
1 · day
1
sc for a total of 21 days. This dose has previously been shown to
improve LV hemodynamics with little increase in heart rate (21, 27).
Untreated rabbits were studied 3 wk after surgery.
Echocardiographic-Doppler studies.
Rabbits were anesthetized with ketamine (50 mg/kg) and xylazine (5 mg/kg) intramuscularly, placed in the left lateral decubitus position,
and imaged with a 7.5-MHz mechanical transducer (Sonos 100, Hewlett-Packard) (29). LV outflow tract (LVOT) diameter was measured in
a parasternal long-axis view. A midventricular short-axis view was
obtained, and the M-mode cursor crossed the anterior wall and bisected
the papillary muscles. LV cavity dimensions were measured from the
M-mode tracing using the leading edge method. Fractional shortening was
calculated as
|
(1) |
|
(2) |
Myocyte isolation. Rabbits were killed by injection of Beuthanasia (0.5 ml, Schering-Plow Animal Health). The heart was excised and perfused with a Ca2+-free, HEPES-buffered Tyrode solution (37°C) followed by a solution containing 0.1 mmol/l Ca2+, 0.1% collagenase (Cls II, Worthington), and 0.01% protease (type XIV; Sigma). After 15 min, the chambers were separated and weighed. The left ventricle was trimmed so that a 2- to 3-mm rim of surviving tissue remained around the clearly demarcated scar (20). This rim of tissue was then dissected free from the scar, minced, and strained. Tissue from the same region of the heart was used in the control rabbits and the infarcted rabbits. Myocytes from the region adjacent to the scar were used preferentially because previous work shows that there is greater cellular hypertrophy in this region (25). The yield of viable myocytes was ~ 40-50% in all groups of rabbits. Only cells with rectangular shapes, clear striations, and absence of spontaneous contractions or membrane blebs were studied.
General features of single myocyte studies.
Studies were performed within 8 h after cell dissociation. The cells
were affixed with lamanin to a glass coverslip that formed the bottom
of a bath and then perfused with Tyrode solution (concentration in
mmol/l: 138 NaCl, 1.0 MgCl2, 4.4 KCl, 11.0 dextrose, 2.7 CaCl2, and 12.0 HEPES, pH adjusted to 7.4 with NaOH;
30°C). This temperature was used to minimize rundown of
currents and to optimize longevity of the cells. Previous work suggests that contraction-frequency relationships are not substantively different at 32°C or 37°C (11). Cells
were viewed with an inverted microscope (Nikon Diaphot 200 or Olympus
IX50). Cell motion was recorded using a video edge detection system
(Crescent Electronics). Solutions superfusing individual cells were
rapidly changed using a modification of a previously described solution
switcher (35). The modified switcher utilized a single piece of
double-barreled square glass tubing that was pulled to a fine tip over
a flame. Whole cell patch-clamp studies were performed using
borosilicate microelectrodes (Corning 7052; resistance 1-2 M
).
Current and cell motion were digitized at a sampling frequency of 1 ms
(Digidata 1200, Axon Instruments) and stored on a personal computer for
later analysis using pCLAMP 6 software (Axon Instruments). The low-pass
Bessel filter on the Axopatch amplifier was set at 5 kHz for
voltage-clamp experiments. During measurement of action potentials,
membrane potential was sampled every 0.5 ms and the band-pass filter on the Axoclamp 2B amplifier was set at 3 kHz. No detectable aliasing occurred under these conditions.
Shortening-interval relationships in single myocytes. Frequency-dependent effects on contractility were measured in field-stimulated myocytes. This approach was used so that intracellular ionic composition and signaling processes were not disturbed and could change with stimulation rate. Five-millisecond pulses were applied with a pair of parallel platinum wires. Each cell was initially stimulated at 0.33 Hz for at least 1 min. Stimulation rate was successively increased from 0.33 to 0.5, 1.0, 2.0, and 3.0 Hz. Four consecutive steady-state contractions were recorded at each rate.
Measurement of action potentials. Action potentials were measured using the bridge mode of the voltage-clamp circuit. The Tyrode solution contained 1 mmol/l CaCl2 and the pipette solution contained (concentration in mmol/l) 113 KCl, 5.5 dextrose, 5.0 K2ATP, 10 HEPES, 0.02 EGTA, 0.5 MgCl, and 10 NaCl, with pH adjusted to 7.1 using KOH. Five-millisecond current injections were adjusted to a level ~10% above threshold. Cells were stimulated at 0.33 Hz for at least 2 min, and then action potentials were measured at 0.33, 0.5, 1.0, 2.0, and 3.0 Hz. Resting membrane potential, peak potential, and time to 20%, 50%, and 90% repolarization (APD20, APD50, and APD90) were measured from 3-4 consecutive action potentials.
SR Ca2+ content at
different stimulation rates.
SR Ca2+ content was measured based on published methods
(36). The pipette solution contained (concentration in mmol/l) 130 CsCl, 5.5 dextrose, 5.0 K2ATP, 10 HEPES, 0.02 EGTA, 0.5 MgCl, and 10 NaCl, with pH adjusted to 7.1 using CsOH. Before each
recording, a 10-s train of conditioning pulses (300 ms) from
80
mV to +10 mV was applied. Steady-state SR Ca2+ loading
during the train was inferred because the amplitude of cell shortening
increased over the first few beats and reached a plateau within
4-5 beats. During each train, the conditioning pulses were applied
at frequencies of 0.5, 1.0, or 2.0 Hz. All three frequencies were used
sequentially in each cell. These frequencies were chosen because during
field stimulation the changes in contractile amplitude were largest
between 0.5 and 2.0 Hz. A 1-min recovery was interposed among each of
the three trials. After each conditioning train, the cell was held at
80 mV and 2 s later the superfusing solution was rapidly (within
~150 ms) changed to normal Tyrode solution containing caffeine (20 mmol/l). The caffeine solution was applied for ~5 s. The application
of caffeine induced a large contraction accompanied by a decaying
inward current. The inward current induced by caffeine has previously
been shown to be caused by the Na+/Ca2+
exchanger, which extrudes the Ca2+ released from the SR
(36). Integration of the inward current gives an estimate of the total
amount of Ca2+ released from the SR. We used the holding
current as the baseline for the integration.
55 mV.
The area under the initial component of the capacity transient was
derived by integration (pCLAMP 6 software) and divided by the voltage
step. For measurements of Cm, signals were
digitized at a sampling rate of 250 µs.
Measurements of intracellular
Ca2+ transients.
Aliquots of dissociated myocytes were incubated with 1 µmol/l fluo 3 acetoxymethylester (Molecular Probes) for 20 min at room temperature. Myocytes were imaged with a laser scanning
confocal microscope (Bio-Rad 1024) attached to an inverted microscope
(Nikon Diaphot) equipped with a ×40 oil-immersion objective
(NA = 1.3). Images were recorded in the line scan mode with the scan
line usually oriented along the long axis of the cell.
Ca2+ transients were elicited by field
stimulation at 0.5 Hz. Excitation light (488 nm) was produced with
an argon laser. Emitted fluorescence was measured at 520 nm. The Tyrode
solution for these experiments (23°C) contained
0.5 mM probenecid to prevent loss of dye from the cells. Transients were constructed by stacking 512 consecutive line
scans (at 6-ms intervals) and performing a time-intensity plot
using NIH Image software. Intracellular Ca2+
concentration ([Ca2+]i) was
calculated as follows: Kd × (F/F0)/[(Kd/[Ca2+]i,rest) + 1
(F/F0)], where Kd is
the dissociation constant for fluo 3, F is the fluorescence intensity,
and F0 is resting fluorescence intensity (33). The
Kd was assumed to be 1.1 µmol/l, and resting
[Ca2+]i
([Ca2+]i,rest) was assumed to be
150 nmol/l (33). The time to peak and the time from peak to 50%
decline in [Ca2+]i were measured
for each cell.
Statistics. All data are shown as means ± SE. Comparisons of action potentials, currents, Ca2+ transients, and contractions at each stimulation frequency in myocytes from control, untreated MI, and DITPA-treated MI hearts were performed using a one-factor ANOVA. When appropriate, a post hoc Student-Newman-Keuls multiple comparisons test was used to look for specific intergroup differences (Primer of Biostatistics, McGraw Hill). A probability of <0.05 was considered to be significant.
| |
RESULTS |
|---|
|
|
|---|
Thirty-seven rabbits were used in these studies (control = 14, MI = 15, and DITPA-treated MI = 8). The number of cells used for each protocol
are shown in the figures. Infarct size was not different in the
untreated and DITPA-treated groups (Table
1). Rabbits with untreated MI showed
evidence of chronic LV dysfunction, including increased atrial and
right ventricular weights (Table 1). Echocardiographic measurements
revealed significant LV dilatation, systolic dysfunction, and decreased
cardiac output in the untreated MI rabbits (Table
2). DITPA treatment did not affect chamber weights but attenuated the LV dilatation and systolic dysfunction that
were seen in the untreated MI rabbits (Tables 1 and 2).
|
|
Single myocyte shortening-frequency relationships.
Compared with control myocytes, contractions in MI myocytes were
smaller in magnitude, had decreased rates of shortening and relengthening, and had markedly prolonged time to peak shortening (Figs. 1 and
2). Increasing stimulation frequency was
associated with significant increases in contractility in control
myocytes (Figs. 1 and 2). However, there was little increase in
contractility when pacing rate was increased in the MI
myocytes. At a stimulation rate of 2.0 Hz, the untreated MI myocytes
did not relax fully before the next contraction (Fig. 1). In
contrast, all of the control and DITPA-treated MI myocytes were able
to fully relax at a stimulation rate of 2.0 Hz. None of
the myocytes from the untreated MI rabbits contracted
regularly during every stimulus at 3.0 Hz (i.e., alternans
developed). Thirteen of 42 control (31%), and 15 of 26 DITPA-treated
MI myocytes (58%) contracted fully during each stimulus at
3.0 Hz. DITPA treatment almost completely prevented the
frequency-dependent abnormalities of contractility and relaxation
in MI myocytes (P = not significant vs. control).
|
|
Action potential duration and stimulation frequency.
Resting membrane potential was similar in myocytes from all three
groups (Figs. 3 and
4A). The peak of the
action potential was slightly but significantly more positive in the MI
myocytes compared with control or DITPA-treated MI myocytes (Fig.
4B). At 0.33-2.0 Hz, action potential duration was
significantly prolonged in myocytes from infarcted hearts compared with
control myocytes (Figs. 3 and 4). The early portion of the plateau
(APD20) was only slightly prolonged, whereas the later
portions (APD50 and APD90) were markedly
prolonged (Fig. 4C-4E). When stimulation rate was
increased, action potential duration shortened in both control and MI
myocytes. At a rate of 3.0 Hz, APD90 was not different in
control and MI myocytes. In myocytes from DITPA-treated MI rabbits,
action potential configuration was not different from controls at all
stimulation frequencies (Figs. 3 and 4).
|
|
SR Ca2+ content and
stimulation frequency.
Examples of SR Ca2+ content measurements at different
stimulation frequencies are shown in Fig.
5, and summary data are shown in Fig.
6. We found that releasable SR
Ca2+ stores were increased in myocytes from the infarcted
hearts at the slowest stimulation rate (0.5 Hz; Fig. 6A). When
stimulation rate was increased, SR content increased significantly in
control myocytes (slope = 0.36 ± 0.05) but not in untreated MI
myocytes (slope = 0.09 ± 0.07; Fig. 6B). Myocytes from
DITPA-treated MI rabbits showed an intermediate frequency-dependent
increase in SR Ca2+ content (slope = 0.18 ± 0.04; Fig.
6B).
|
|
Intracellular Ca2+
transients.
Compared with control myocytes, MI myocytes had a lower peak
[Ca2+]i, prolonged time to peak
[Ca2+]i, and slower decline in
[Ca2+]i (Fig.
7). The amplitude and time course of
Ca2+ transients were not different between DITPA-treated MI
and control myocytes.
|
| |
DISCUSSION |
|---|
|
|
|---|
There were four main findings in the current study: 1) there is marked blunting of the contraction-frequency and relaxation-frequency relationships in single myocytes from the infarcted rabbit heart; 2) treatment with the thyroid hormone analog DITPA almost completely prevented the flattening of the contraction- and relaxation-frequency relationships after MI; 3) DITPA treatment prevented the infarction-induced increases in duration of both action potentials and isotonic contractions; and 4) DITPA treatment partially prevented a reduction in the ability of the SR to accumulate Ca2+ at faster stimulation rates and also improved the rate of decline of intracellular Ca2+ transients.
A flattened force-frequency relationship has been widely described in both human and experimental forms of heart failure (3, 11, 16, 20, 22) with a few exceptions (1). Whereas the exact causes of the blunted contraction-frequency relationship are still unclear, levels of SERCA2a protein have been reported to correlate with rate-dependent changes in contractile force (16). Interestingly, the force-frequency relationship in myocardium from failing human hearts can be improved acutely by administration of forskolin (23). Mulieri et al. (23) hypothesized that the forskolin-induced enhancement of the force-frequency relationship was attributable to an increase in intracellular cAMP levels. Presumably the increase in cAMP would promote SR Ca2+ uptake due to phosphorylation of phospholamban. Although these data are promising, chronic treatment of heart failure patients with agents that act primarily by increasing cAMP has been disappointing (30). Furthermore, cAMP-enhancing drugs may significantly reduce the economy of excitation-contraction coupling and the overall economy of contraction in failing human myocardium (15). The concept of improving SR function in the treatment of heart failure, however, may still be valid, and agents that improve SR function by alternate mechanisms may prove clinically useful.
We found that DITPA significantly improved the single myocyte shortening-frequency relationship in infarcted hearts. The time course of intracellular Ca2+ transients were similarly enhanced by DITPA treatment. These effects could be explained by a DITPA-mediated increase in the expression of SERCA2a relative to phospholamban. Both of these proteins are believed to be under transcriptional regulation by T4 (2, 8, 31). Preliminary data suggest that DITPA may also affect the expression of sarcolemmal and SR proteins important for excitation-contraction coupling (28). Finally, DITPA might indirectly affect Ca2+ cycling through signaling pathways that modulate excitation-contraction coupling proteins (e.g., Ca2+/calmodulin-dependent kinase).
At stimulation rates of 0.33-2.0 Hz, action potential duration was significantly prolonged in the MI but not in the DITPA-treated MI myocytes. Action potential duration is determined largely by the balance of the depolarizing L-type Ca2+ current and the delayed rectifier K+ currents, rapidly activating (IKr) and slowly activating (IKs) (18). Other repolarizing K+ currents [i.e., transient outward current (Ito) and inward rectifier K+ current (IK1)] may also contribute to phase 3 repolarization, although they are probably less important than IK. Several prior studies suggest that decreased expression and density of several of these K+ currents may underlie the action potential prolongation that is characteristic in hypertrophy or heart failure (24). In contrast, hyperthyroidism is believed to cause shortening of action potential duration (7). This may occur because of both acute effects on K+ currents (32) and chronic effects on K+ channel expression (34, 37). Our finding that DITPA restored a normal action potential duration in MI myocytes suggests that DITPA may have prevented some of the abnormalities of K+ channel expression or function commonly seen in cardiac overload.
The effects of DITPA on action potential duration may be very important for the process of excitation-contraction coupling. Prolongation of action potentials may affect sarcolemmal Ca2+ fluxes via L-type Ca2+ channels and the Na+/Ca2+ exchanger (9). Action potential morphology affects both the electrical driving forces on Ca2+ and the extent of voltage-dependent inactivation of Ca2+ channels. Under steady-state conditions, prolongation of action potential duration has been reported to increase SR Ca2+ content but decrease the peak Ca2+ current and the peak rate of rise of the intracellular Ca2+ transient (9). These data are consistent with our observation that SR Ca2+ content tended to be enhanced in the MI myocytes at the slower stimulation rates, even though peak cellular shortening rate was decreased (Figs. 2 and 6). Because of the beneficial effects on action potential duration, it is conceivable that DITPA or similar compounds could prove to be useful inotropic agents with a smaller risk of provoking arrhythmias or sudden death. DITPA might be particularly useful for bradycardia- or pause-dependent arrhythmias, because the effects of DITPA on action potential duration appear to be more pronounced at slower stimulation rates.
Myocytes from infarcted hearts did not show increases in SR Ca2+ content when stimulation rate was increased. Although the use of caffeine may have limitations in determining the absolute quantity of Ca2+ in the SR, the relative changes for each cell should be reliable. Another consideration in the interpretation of these experiments is that the Na+/Ca2+ exchanger current density is increased in MI myocytes (20). Such a change should increase the peak amplitude of the caffeine-induced inward current for a given SR release, but the current integral (the total amount of Ca2+ extruded) should not change (38).
The main factors producing normal rate-dependent enhancement of SR Ca2+ content include increased time-averaged sarcolemmal Ca2+ entry via L-type channels and enhancement of SR Ca2+ uptake due to phosphorylation of phospholamban (5). It is possible that the blunted frequency staircase in diseased hearts reflects abnormalities of one of these mechanisms. However, it is also possible that the failure to increase SR Ca2+ content in the postinfarction myocytes occurs because the SR is already "full," even at slower stimulation rates. Such a situation could conceivably result if the fractional SR Ca2+ release were diminished. In normal myocytes, the fractional SR release has been shown to increase as the total SR Ca2+ content increases (4). Inability to increase the fractional SR Ca2+ release might result from impaired coupling of sarcolemmal Ca2+ entry and SR Ca2+ release. This hypothesis has a precedent because some investigators have shown evidence of defective triggering of SR Ca2+ release in myocytes from failing hearts (13). Although we did not measure the "gain" of SR Ca2+ release in these studies, our data are compatible with an alteration in the sensitivity of the Ca2+ release apparatus.
Our data expand on previous work with thyroid hormone (10) by demonstrating that the T4 analog DITPA restores frequency potentiation in single myocytes from a postinfarction model. Compared with T4, DITPA has the clear advantage of not causing tachycardia. The current work extends our knowledge about the mechanism(s) of action of thyroid hormone analogs by demonstrating for the first time that DITPA prevents frequency-dependent abnormalities of SR function in intact myocytes. Preliminary studies suggest that DITPA enhances the expression of SR proteins involved in Ca2+ cycling (28).
Limitations. There is potential for significant selection bias or sampling error introduced by studying single cells isolated from infarcted hearts. By studying a fairly large number of cells (20-30 per group, per protocol) with only 5-10 cells coming from any one rabbit, sampling errors should have been minimized. Even so, it is possible that the "sickest" cells might not survive the isolation process. We do not think this is the case because cells isolated from the infarcted rabbit heart have the expected morphological and electrophysiological characteristics of hypertrophied or failing hearts (i.e., myocyte hypertrophy, action potential prolongation, and abnormalities of contraction and relaxation). It is possible, although we think it is unlikely, that the effects we attribute to DITPA were the indirect result of daily injections rather than a direct effect of the agent. We cannot rule out this possibility because we did not give vehicle injections to the untreated MI or control rabbits. Another issue is that the effects of DITPA are complex and almost certainly multifactorial in etiology. Despite some uncertainty about the underlying mechanisms, the demonstration of benefit at the level of the single myocyte is clear and there is substantial indirect evidence that SR function was improved following treatment.
In conclusion, these results show for the first time that DITPA treatment prevents prolongation of action potential duration and the development of abnormal contractile responses to increasing stimulation frequency in myocytes from infarcted hearts. Our data are consistent with a DITPA-mediated enhancement of SR function, although the exact mechanism of action remains to be determined. This study demonstrates that DITPA exerts direct effects on the myocyte and furthers our understanding of thyroid hormone analogs in the treatment of heart failure.| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by grants from the Department of Veterans Affairs (to S. E. Litwin and G. Pennock) and a Grant in Aid from the Western Affiliate of the American Heart Association (to S. E. Litwin).
| |
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: S. E. Litwin, Cardiovascular Division, Univ. of Utah Hospital, 50 N. Medical Dr., Salt Lake City, UT 84132 (E-mail: sheldon.litwin{at}hsc.utah.edu).
Received 1 June 1999; accepted in final form 13 October 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anand, I. S.,
D. Liu,
S. S. Chugh,
A. J. C. Prahash,
S. Gupta,
R. John,
F. Popescu,
and
Y. Chandrashekhar.
Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction.
Circulation
96:
3974-3984,
1997
2.
Arai, M.,
K. Otsu,
D. H. MacLennan,
N. R. Alpert,
and
M. Periasamy.
Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins.
Circ. Res.
69:
266-276,
1991
3.
Asanoi, H.,
S. Ishizaka,
S. Joho,
T. Kameyama,
H. Inoue,
and
S. Sasayama.
Altered inotropic and lusitropic responses to heart rate in conscious dogs with tachycardia-induced heart failure.
J. Am. Coll. Cardiol.
27:
728-735,
1996[Abstract].
4.
Bassani, J. W. M.,
W. Yuan,
and
D. M. Bers.
Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes.
Am. J. Physiol. Cell Physiol.
268:
C1313-C1329,
1995
5.
Bassani, R. A.,
A. Mattiazzi,
and
D. M. Bers.
CaMKII is responsible for activity-dependent acceleration of relaxation in rat ventricular myocytes.
Am. J. Physiol. Heart Circ. Physiol.
268:
H703-H712,
1995
6.
Bers, D. M.
Control of cardiac contraction by SR Ca release and sarcolemmal Ca fluxes.
In: Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer Academic, 1991.
7.
Binah, O.,
I. Rubinstein,
and
E. Gilat.
Effects of thyroid hormone on the action potential and membrane currents of guinea pig ventricular myocytes.
Pflügers Arch.
409:
214-216,
1987[ISI][Medline].
8.
Boerth, S. R.,
and
M. Artman.
Thyroid hormone regulates Na+-Ca2+ exchanger expression during postnatal maturation and in adult rabbit ventricular myocardium.
Cardiovasc. Res.
31:
E145-E132,
1996.
9.
Bouchard, R. A.,
R. B. Clark,
and
W. R. Giles.
Effects of action potential duration on excitation-contraction coupling in rat ventricular myocytes: action potential clamp measurements.
Circ. Res.
76:
790-801,
1995
10.
Chang, K. C.,
V. M. Figueredo,
J. H. Schreur,
K. Kariya,
M. W. Weiner,
P. C. Simpson,
and
S. A. Camacho.
Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and
-myosin heavy chain in rat hearts.
J. Clin. Invest.
100:
1742-1749,
1997[ISI][Medline].
11.
Davies, C. H.,
K. Davia,
J. G. Bennet,
J. R. Pepper,
P. A. Poole-Wilson,
and
S. E. Harding.
Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure.
Circulation
92:
2540-2549,
1995
12.
Gheorghiade, M.,
and
R. O. Bonow.
Chronic heart failure in the United States: a manifestation of coronary artery disease.
Circulation
97:
282-289,
1998
13.
Gomez, A. M.,
H. H. Valdivia,
H. Cheng,
M. R. Lederer,
L. F. Santana,
M. B. Cannell,
S. A. McCune,
R. A. Altschuld,
and
W. J. Lederer.
Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure.
Science
276:
800-806,
1997
14.
Hasenfuss, G.
Animal models of human cardiovascular disease, heart failure, and hypertrophy.
Cardiovasc. Res.
39:
60-76,
1998
15.
Hasenfuss, G.,
L. A. Mulieri,
P. D. Allen,
H. Just,
and
N. R. Alpert.
Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium.
Circulation
94:
3155-3160,
1996
16.
Hasenfuss, G.,
H. Reinecke,
R. Struder,
M. Meyer,
B. Pieske,
J. Holtz,
C. Holubarsch,
H. Posival,
H. Just,
and
H. Drexler.
Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium.
Circ. Res.
75:
434-442,
1994
17.
Hoit, B. D.,
C. M. Pawloski-Dahm,
Y. Shao,
M. Gabel,
and
R. A. Walsh.
The effects of a thyroid hormone analog on left ventricular performance and contractile and calcium cycling proteins in the baboon.
Proc. Assoc. Am. Physicians
109:
136-145,
1997[ISI][Medline].
18.
Jurkiewicz, N. K.,
and
M. C. Sanguinetti.
Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: specific block of rapidly activating delayed rectifier K+ current by dofetilide.
Circ. Res.
72:
75-83,
1993
19.
Khoury, S. F.,
B. D. Hoit,
D. Vrushank,
C. M. Pawloski-Dahm,
Y. Shao,
M. Gabel,
M. Periasamy,
and
R. A. Walsh.
Effects of thyroid hormone on left ventricular performance and regulation of contractile and Ca2+ cycling proteins in the baboon: implications for the force-frequency and relaxation-frequency relationships.
Circ. Res.
79:
727-735,
1996
20.
Litwin, S. E.,
and
J. H. B. Bridge.
Enhanced sodium-calcium exchange in the infarcted heart: implications for excitation-contraction coupling.
Circ. Res.
81:
1083-1093,
1997
21.
Mahaffey, K. W.,
T. E. Raya,
G. D. Pennock,
E. Morkin,
and
S. Goldman.
Left ventricular performance and remodeling in rabbits after myocardial infarction. Effects of a thyroid analogue.
Circulation
91:
794-802,
1995
22.
Mulieri, L. A.,
G. Hasenfuss,
B. J. Leavitt,
P. D. Allen,
and
N. R. Alpert.
Altered myocardial force-frequency relation in human heart failure.
Circulation
85:
1743-1750,
1992
23.
Mulieri, L. A.,
B. J. Leavitt,
B. J. Martin,
J. R. Haeberle,
and
N. R. Alpert.
Myocardial force-frequency defect in mitral regurgitation heart failure is reversed by forskolin.
Circulation
88:
2700-2704,
1993
24.
Naubauer, M.,
and
S. Kaab.
Potassium channel down-regulation in heart failure.
Cardiovasc. Res.
37:
324-334,
1998[ISI][Medline].
25.
Olivetti, G.,
J. M. Capasso,
L. G. Meggs,
E. H. Sonnenblick,
and
P. Anversa.
Cellular basis of chronic ventricular remodeling after myocardial infarction in rats.
Circ. Res.
68:
856-869,
1991
26.
Pennock, G. D.,
T. E. Raya,
J. J. Bahl,
S. Goldman,
and
E. Morkin.
Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity.
J. Pharmacol. Exp. Ther.
263:
163-169,
1992
27.
Pennock, G. D.,
T. E. Raya,
J. J. Bahl,
S. Goldman,
and
E. Morkin.
Combination treatment with captopril and the thyroid hormone analogue 3,5-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure.
Circulation
88:
1289-1298,
1993
28.
Pennock, G. D.,
C. E. Summers,
P. H. Spooner,
and
S. E. Litwin.
3,5-Diiodothyropropionic acid (DITPA) prevents abnormalities of SR calcium transport and protein expression in postinfarction heart failure (Abstract).
Circulation
98, Suppl I:
I-104,
1998.
29.
Pennock, G. D.,
D. D. Yun,
P. G. Agarwal,
P. H. Spooner,
and
S. Goldman.
Echocardiographic changes after myocardial infarction in a model of left ventricular diastolic dysfunction.
Am. J. Physiol. Heart Circ. Physiol.
273:
H2018-H2029,
1997
30.
Remme, W. J.
Inodilator therapy for heart failure. Early, late, or not at all?
Circulation
87, Suppl 5:
IV97-IV107,
1993.
31.
Rohrer, D.,
and
W. H. Dillmann.
Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart.
J. Biol. Chem.
263:
6941-6944,
1988
32.
Sakaguchi, Y.,
G. Cui,
and
L. Sen.
Acute effects of thyroid hormone on inward rectifier potassium channel currents in guinea pig ventricular myocytes.
Endocrinology
137:
4744-4751,
1996[Abstract].
33.
Satoh, H.,
H. Katoh,
P. Velez,
M. Fill,
and
D. M. Bers.
Bay K 8644 increases resting Ca2+ spark frequency in ferret ventricular myocytes independent of Ca influx: contrast with caffeine and ryanodine effects.
Circ. Res.
83:
1192-1204,
1998
34.
Shimoni, Y.,
C. Fiset,
R. B. Clark,
J. E. Dixon,
D. McKinnon,
and
W. R. Giles.
Thyroid hormone regulates postnatal expression of transient K+ channel isoforms in rat ventricle.
J. Physiol. (Lond.)
500:
65-73,
1997[ISI][Medline].
35.
Spitzer, K. W.,
and
J. H. B. Bridge.
A simple device for rapidly exchanging solutions surrounding a single cardiac cell.
Am. J. Physiol. Cell Physiol.
256:
C441-C447,
1989
36.
Varro, A.,
N. Negretti,
S. B. Hester,
and
D. A. Eisner.
An estimate of the calcium content of the sarcoplasmic reticulum in rat ventricular myocytes.
Pflügers Arch.
423:
158-160,
1993[ISI][Medline].
37.
Wickenden, A. D.,
R. Kaprielian,
T. G. Parker,
O. T. Jones,
and
P. H. Backx.
Effects of development and thyroid hormone on K+ currents and K+ channel gene expression in rat ventricle.
J. Physiol. (Lond.)
504:
271-286,
1997[ISI][Medline].
38.
Yao, A.,
Z. Su,
A. Nonaka,
I. Zubair,
L. Lu,
K. D. Philipson,
J. H. Bridge,
and
W. H. Barry.
Effects of overexpression of the Na+-Ca2+ exchanger on [Ca2+]i transients in murine ventricular myocytes.
Circ. Res.
82:
657-65,
1998
This article has been cited by other articles:
![]() |
W. Zheng, R. M. Weiss, X. Wang, R. Zhou, A. M. Arlen, L. Lei, E. Lazartigues, and R. J. Tomanek DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1994 - H2000. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, W. Zheng, L. P. Christensen, and R. J. Tomanek DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H613 - H618. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Litwin, D. Zhang, and J. H. B. Bridge Dyssynchronous Ca2+ Sparks in Myocytes From Infarcted Hearts Circ. Res., November 24, 2000; 87(11): 1040 - 1047. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |